Anti-Infective Agents Market

Anti-Infective Agents Market Outlook (2022-2032)

The global anti-infective agents market is expected to be worth US$ 141 Billion in fiscal year 2022, up from US$ 136 Billion in fiscal year 2021. From 2022 to 2032, the market is expected to grow at a 3.3% CAGR, reaching a value of US$ 195.8 Billion by the end of 2032.

Over the course of the projection period, new medication approvals are also anticipated to boost market growth. For instance, the Food and Drug Administration (FDA) authorized medications in 2016 such as Zepatier by Merck, which treats adult patients with chronic Hepatitis C virus (HCV) genotypes 1 or 4 infections, as well as Descovy by Gilead, which treats HIV-1 infection. From 2022 through 2032, these advancements will result in a greater need for anti-infective drugs

According to estimates, the market will rise as a result of factors including the rising prevalence of infectious disorders and antimicrobial resistance to already available anti-infective drugs. In addition, rising health consciousness, awareness of the accessibility of diagnostics for infectious illnesses, and preventable risks related to early detection are some of the elements anticipated to support development.

The FDA-approved, modified antibiotics Orbactiv (Oritavancin), Dalvance (Dalbavancin), Zevtera (Ceftobiprole), and Sivextro have recently been introduced by companies for the treatment of acute bacterial skin and soft tissue infections (Tedizolid). In the next few years, the anti-infective agents market is anticipated to rise as a result of the growing prevalence of these anti-infective treatments due to their enhanced efficacy.

Report Attributes	Details
Anticipated Base Year Value (2021)	US$ 136 Billion
Expected Market Value (2022)	US$ 141 Billion
Projected Forecast Value (2032)	US$ 195.8 Billion
Global Growth Rate (2022-2032)	3.3%
CAGR of North America (2022)	4%
CAGR of APAC (2022-2032)	3.1%
Prominent Players in The Global Market	Novartis AG Sanofi SA Pfizer Inc. Johnson & Johnson Services Inc. Alembic Pharmaceuticals Mankind Pharma, Merck & Co. Inc. Bayer AG Gilead Sciences GSK

2017-2021 Anti-Infective Agents Market Demand Analysis Vs. Forecast 2022-2032

The global anti-infective agents market grew at a CAGR of 2.2% from 2017 to 2021, as per Fact.MR, a provider of market research and competitive intelligence. Due to the limitations put in place by several nations during the COVID-19 epidemic, numerous towns, industries, companies, and lifestyles were negatively impacted. The COVID-19 epidemic touched almost every industry.

Anti-infective agent use, however, has drawn attention in an effort to stop the transmission of the SARS-CoV-2 virus and other infectious diseases that aggravate the state of the affected population. The use of antimicrobial peptides and antibodies as anti-infective agents against the SARS-CoV-2 virus was proposed in an article titled "Antimicrobial Resistance in the COVID-19 Landscape: Is There an Opportunity for Anti-Infective Antibodies and Antimicrobial Peptides?" that was published in the journal Frontiers in Immunology in June 2022.

During the last two years, the market grew considerably as a result of the widespread usage of anti-infective agents to stop the spread of COVID-19 among the populace.

Due to the increasing frequency of certain diseases, growing awareness campaigns, and increased investments in anti-infective medication research and development, the market for anti-infective agents is predicted to expand gradually. Since many years ago, anti-infectives agents have been an important market for pharmaceutical businesses. The rate of infection has considerably increased during the past 20 years, especially in low- and middle-income nations.

Prominent Growth Drivers Influencing Anti-Infective Agents Industry

Increasing incidence of several infectious diseases across the globe

The primary factor fueling the market's expansion is the rising prevalence of a number of infectious diseases in developed and developing economies, including various strains of influenza, diarrhea, hepatitis, as well as urinary tract infections, which call for increased attention from the biotechnology and pharmaceutical industries.

For instance, according to a study published in the journal Frontiers in Public Health in October 2021 and titled "A Cross-Sectional Assessment of Urinary Tract Infections Among Geriatric Patients: Prevalence, Medication Regimen Complexity, and Factors Associated with Treatment Outcomes," urinary tract infections result in over 7 million hospital visits and 100,000 hospitalizations annually. The growing need for anti-infective medications to treat these disorders is anticipated to fuel market expansion.

Additionally, there has been a large increase in the number of multi drug resistant organisms in various regions of the world, which emphasizes the significance of anti-infective agent innovation even more. To raise public knowledge of infectious illnesses, a number of institutes have launched various programmes or campaigns.

To increase awareness of antimicrobial resistance, the World Health Organization, for instance, held the World Antimicrobial Awareness Week (WAAW) in November 2021 with the theme, "Spread Awareness, Stop Resistance." Such factors can be predicted to boost the demand in the global market for anti-infective agents.

Rising number patients who require long term treatments to boost the demand

The patient population is quite diverse, necessitating extended hospital stays as well as home care services. Additionally, it has been noted that governments in nations with rapid economic growth are becoming more interested in working with hospitals and multinational pharmaceutical companies to increase the rate at which antiviral agents are distributed to those who need them in a given region of the nation.

For instance, Pfizer Inc. stated in November 2021 that it had reached a deal with the US government to provide 10 million treatment courses of PAXLOVID, an experimental oral antiviral candidate for COVID-19. The business had also started bilateral outreach to almost 100 nations worldwide and had signed multiple advance purchase agreements with different nations. Such factors are predicted to increase significantly, which is likely to boost sales during the forecast period.

What Could Possibly Hinder Anti-Infective Agents Industry Demand?

High cost of the drugs and poor reimbursement policies to hinder growth

The development of anti-infective medication resistance and its accompanying adverse effects, as well as a lack of resources in healthcare institutions, particularly in emerging nations, limit the study market's potential expansion.

The demand for items in this market is also declining as a result of the high cost of anti-infective medications. Additionally, the inadequate payment practises of various countries are inhibiting the market for anti-infectives from expanding smoothly on a worldwide scale.

Category-wise Insights

Which type is expected to gain traction during 2022-2032?

The anti-viral segment will gain the dominant Market Share

In the year 2021, the anti-viral segment by product type gained the maximum market share of almost 61%. This segment is expected to maintain its dominance throughout the forecast period too.

As various pharmaceutical companies look for ways to develop in lower- and middle-income nations, where the risk of epidemic infection is high, the anti-viral agents are anticipated to see rapid expansion throughout the course of the projection period.

Antiviral medications are prescription treatments that are mostly used to treat the flu, according to information published by the US Centers for Disease Control and Prevention in August 2021. Antiviral medications aid in reducing the chance of infection and shortening the length of the sick person's illness.

Infectious illness occurrence is increasing, public awareness of these diseases is expanding, and more research and development is being done in this field, all of which are contributing to the market's expansion. Due to the rising demand for anti-viral medications, a number of market companies have been concentrating on their manufacture and manufacturing.

For instance, the public health group Medicines Patent Pool (MPP), which is supported by the United Nations, and the pharmaceutical corporation Merck & Co. Inc. inked a voluntary license deal in October 2021. The goal of the agreement was to make it easier for people all over the world to obtain molnupiravir, an experimental oral COVID-19 antiviral drug used to treat mild-to-moderate COVID-19 among adults who run the risk of developing.

Which route of administration segment will be used for these products more often?

The oral route application of anti-infective agents will become dominant

The oral-route application segment will be the fastest growing segment during the forecast period with a 3.4% CAGR. In the year 2021, this segment acquired almost 32% of the market share.

Due to the development of new products and the existence of a robust pipeline, the oral route of administration will hold the majority of the market share in 2022. Oral treatments lessen hospital stays and the problems associated with central lines used for intravenous medication delivery. Such factors are expected to push the demand to new heights in the next ten years.

Region-wise Analysis

What is the outlook of the North American anti-infective agents market?

Advanced healthcare systems with constant developments to propel the regional demand

With a CAGR of 4% from 2022 to 2032, the North American region is anticipated to considerably contribute to the market growth during the research period. Over the course of the projection period, the market is anticipated to be driven by elements including an advanced healthcare infrastructure, high societal awareness, well-established distribution networks, and a strong e-commerce presence in both the United States and Canada.

Antivirals are recommended for the treatment of several infectious disorders by the Centers for Disease Control and Prevention (CDC) in the United States. For instance, the CDC released a leaflet in September 2021 endorsing the use of antiviral medications to treat influenza.

The Food and Drug Administration-approved medications zanamivir, oseltamivir phosphate, baloxavir marboxil, and peramivir were recommended by the CDC. Over the forecast period, such initiatives by governmental health organizations to encourage the use of antivirals in the country are anticipated to fuel the expansion of the anti-infective agents market.

Pharmaceutical businesses are able to expand in this region because of advantageous reimbursement regulations and the strong end-user purchasing power. Additionally, it enables pharmaceutical firms to boost their manufacturing capacities and spend more in financed collaborations with prominent academic medical centers to meet the demand for anti-infective medications across North America.

The market is also being helped by a number of significant companies in the industry. For instance, Phathom Pharmaceuticals, Inc., a biopharmaceutical firm focusing on discovering and commercializing innovative medicines for gastrointestinal illnesses, received FDA approval for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK in May 2022. Such events are anticipated to accelerate market expansion over the anticipated time frame.

What can be expected from the APAC market for anti-infective agents?

Rising economic stability and disposable income will boost the demand during the forecast period

Throughout the anticipated period, APAC exhibits a significant market potential for anti-infective agents. According to the Fact.MR projections, the market will grow with a steady CAGR of 3.1% from 2022-2032.

Due to the existence of generics businesses, rising economic stability, and rising disposable income, the Region will witness increased demand. In the upcoming years, it is anticipated that the aging population and their greater vulnerability to infections would offer a potential development platform.

Start-up Scenario

The various start-ups in the market are aimed at enhancing their product with different varieties for the anti-infective agents.

• Spero Therapeutics is a company that creates drugs to treat drug-resistant bacterial infections. Tebipenem HBr, an oral carbapenem for pediatric infections, SPR720, an oral anti - microbial agent for the non-tuberculous treatment of mycobacterial lung disease, as well as SPR206, an intravenous (IV)-administered succeeding polymyxin analogue for gram-negative infectious diseases are among the novel product applicants the company is evolving.
• Locus Biosciences is a pharmaceuticals developer specializing in infectious illness and inflammatory diseases. For their medications, they work with a variety of anti-infective medicines. The business has created a platform that facilitates the creation of antimicrobials for infectious illnesses and allows for the design and delivery of unique CRISPR-Cas systems to certain bacteria.

Competitive Landscape

Novartis AG, Sanofi SA, Pfizer Inc.; Johnson & Johnson Services Inc.; Alembic Pharmaceuticals, Mankind Pharma, Merck & Co., Inc, Bayer AG; Gilead Sciences, and GSK are a few of the leading businesses in the anti-infective agents market.

• The United States Food and Drug Administration (USFDA) granted Alembic Pharmaceuticals final clearance for its investigational new drug application (ANDA) for Doxycycline Hyclate Delayed-Release Tablets in January 2022. The purpose of Doxycycline Hyclate Delayed-Release Tablets is to prevent the growth of germs that are resistant to antibiotics.
• Novartis announced the adoption of a new organizational structure and operating model in April 2022. These changes are intended to support the firm's aspirations for innovation, development, and productivity as a focused pharmaceuticals company in the ensuing ten years.
• Savior Mankind, a branch of Mankind Pharma devoted to life-saving injectables, was introduced in January 2022. Its medicines range from anti-infectives towards stroke as well as trauma therapy. By creating, manufacturing, commercializing, and providing inexpensive and accessible medications that meet patients' immediate medical requirements, Mankind Pharma hopes to help the community enjoy a healthy lifestyle.

Key Segments Covered in the Anti-Infective Agents Market Report

• By Type :

  • Anti-Viral
  • Anti-Fungal
  • Anti-Bacterial

• By Range :

  • Narrow-Spectrum
  • Broad-Spectrum

• By Route of Administration :

  • IV
  • Oral
  • Topical
  • Others

• By Indication :

  • HIV
  • Tuberculosis
  • Respiratory Infection
  • Pneumonia
  • Others

• By Distribution Channel :

  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce
  • Others

• By Region :

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa (MEA)